Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!).
Daily hassles reported by Dutch multiple sclerosis patients.
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
The translational biology of remyelination: Past, present, and future.
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
Imaging of the spine at 3 tesla.
Response to disease modifying therapies in African Americans with multiple sclerosis.
Back on the scent: the olfactory system in CNS demyelinating diseases.
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
Are there Epstein-Barr virus seronegative patients with multiple sclerosis?
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
Id1 Expression Promotes T Regulatory Cell Differentiation by Facilitating TCR Costimulation.
[Central motor pathways in children with multiple sclerosis].
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon Beta-1a in patients with multiple sclerosis.
Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.

Pages